Skip to main content

Company

Genentech

198 published works

  1. Big Molecule Watch

    Genentech and Biocon Settle Pertuzumab Biosimilar BPCIA Litigation

    By Harrison Gunn

    On October 14, 2026, the U.S. District Court for the District of New Jersey entered an order dismissing without prejudice all claims in Genentech Inc. and Hoffmann-La Roche Inc.’s BPCIA litigation…

  2. Big Molecule Watch

    Celltrion Launches Omalizumab Biosimilar in the United States

    By Wendy Leben

    On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first and only FDA-approved interchangeable biosimilar to Genentech and Novartis’s…

  3. Big Molecule Watch

    Sandoz and mABxience Announce Collaboration for Proposed Emicizumab Biosimilar

    By Shauna Perigo

    On September 18, 2026, Sandoz announced a licensing, development, manufacturing, and commercialization agreement with mAbxience for a proposed biosimilar to Genentech’s HEMLIBRA® (emicizumab).   HEMLIBRA® is approved for the treatment of…

  4. Big Molecule Watch

    Biocon’s Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA’s Tailored Clinical Approach

    By Yoko Bian

    On September 22, 2026, Biocon Biologics Limited (“Biocon”) announced that the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending marketing authorization…

  5. Big Molecule Watch

    Fresenius Kabi and Dr. Reddy’s Announce FDA Approval of Rituximab Biosimilar

    By Sam Herron

    On August 1, 2026, Fresenius Kabi and Dr. Reddy’s Laboratories announced that the FDA had approved Dr. Reddy’s rituximab biosimilar, a biosimilar to Genentech’s RITUXAN® (rituximab).  Rituximab is a monoclonal…

  6. Big Molecule Watch

    Genentech Files BPCIA Patent Infringement Suit Against Biocon Over Proposed PERJETA Biosimilar

    By Sarah Adam

    On July 29, 2026, Genentech, Inc. (“Genentech”) and Hoffmann-La Roche Inc. filed a complaint in the U.S. District Court for the District of New Jersey against Biocon Biologics Inc. (“Biocon”)…

  7. Big Molecule Watch

    Teva and Polpharma Biologics Announce Global Licensing Agreement for Ocrelizumab Biosimilar for Multiple Sclerosis

    By Zachariah Holmes

    On July 9, 2026, Teva Pharmaceuticals International GmbH (“Teva”) and Polpharma Biologics International AG (“Polpharma Biologics”) announced a global licensing agreement under which Teva will obtain exclusive rights to commercialize…

  8. Big Molecule Watch

    Celltrion and Teva’s TRUXIMA® Becomes First Interchangeable Rituximab Biosimilar in U.S.

    By Riley Wyberg

    On July 1, 2026, Celltrion announced that the FDA had granted interchangeability designation to TRUXIMA® (rituximab-abbs), Celltrion and Teva’s biosimilar to Genentech’s RITUXAN®.  With this designation, TRUXIMA® became the first…

  9. Big Molecule Watch

    FDA Expands TOFIDENCE® (tocilizumab-bavi) Label to Include CRS and COVID-19

    By Shauna Perigo

    On June 10, 2026, Organon announced that the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for TOFIDENCE ® (tocilizumab-bavi), an intravenous biosimilar to Genentech’s…

  10. Big Molecule Watch

    FDA Approves Lupin’s Ranibizumab Biosimilar

    By Alex Pressman

    On June 5, Lupin announced that the U.S. Food and Drug Administration (“FDA”) approved RANLUSPEC, a ranibizumab biosimilar to Genentech’s LUCENTIS®. RANLUSPEC, which received European Marketing Authorization earlier this year,…